

Pricing implications for drugs included in China's Rare Diseases Catalogue (RDC)



RADAR
RARE DISEASE ASSESSMENT REVIEWS

The evolution of the RDC in China^{1,2}

- ▶ In 2018, the **First National Rare Diseases Catalogue (RDC)** was released to facilitate better awareness, investment, patient services, and research; designating **121** diseases as rare

- ▶ Criteria for inclusion (four considerations):




On September 18, 2023, the National Health Commission (NHC) announced the **Second RDC**. This list adds **86** diseases and places a stronger emphasis on **nonhereditary conditions** and **rare cancers**

- ▶ Strategic priorities of the Second RDC:



What is the impact of RDC on NRDL price? Small discount protection¹

Percentage discount required for inclusion in the National Reimbursement Drug List (NRDL)**



- ▶ Drugs targeting indications on the RDC are **marginally protected** from NRDL discounts at first listing compared to other high-cost therapy areas like **oncology**
- ▶ Discounts are **generally below** the all-drug average but follow the movement year on year

* No official definition at the time of the First RDC; a definition was released in 2021: incidence of <1/10,000 in newborns, prevalence of <1/10,000, or <140,000 affected individuals

** Based on discount for NRDL inclusion from first indication

Sources

1. Illness Challenge Foundation (2024). Observation Report on the Trends of China's Rare Diseases
2. Tang, M et al. (2023). Release and impact of China's "Second List of Rare Diseases". Intractable & Rare Diseases Research, 12(4), 251-256

Contacts

Chris Jones,
Senior Associate
+44 1223 783926
cjones@crai.com

Charlotte Poon,
Associate Principal
+44 2076 643719
cpoon@crai.com

Harvey Feng,
Associate
+44 1223 783915
wfeng@crai.com

Qinyi Wang,
Associate
+44 1223 783917
qinyiwang@crai.com

CRA Charles River
Associates